Editorial: WW Domain Proteins in Signaling, Cancer Growth, Neural Diseases, and Metabolic Disorders

Nan Shan Chang; Rongtuan Lin; Chun I. Sze; Rami I. Aqeilan

doi:10.3389/fonc.2019.00719

Editorial: WW Domain Proteins in Signaling, Cancer Growth, Neural Diseases, and Metabolic Disorders

Nan Shan Chang, Rongtuan Lin, Chun I. Sze, Rami I. Aqeilan

研究成果: Editorial › 同行評審

原文	English
文章編號	719
期刊	Frontiers in Oncology
卷	9
DOIs	https://doi.org/10.3389/fonc.2019.00719
出版狀態	Published - 2019 8月 2

All Science Journal Classification (ASJC) codes

腫瘤科
癌症研究

存取文件

10.3389/fonc.2019.00719

其它文件與鏈接

引用此

@article{a445e2d29c504cf9939c662b3b6103c6,

title = "Editorial: WW Domain Proteins in Signaling, Cancer Growth, Neural Diseases, and Metabolic Disorders",

author = "Chang, {Nan Shan} and Rongtuan Lin and Sze, {Chun I.} and Aqeilan, {Rami I.}",

note = "Funding Information: Funding. Grant supports for this work: (1) N-SC lab supported by the Ministry of Science and Technology, Taiwan (MOST 107-2320-B-006-058-MY3 and 107-2320-B-006-005) and the National Health Research Institute (NHRI-EX107-10734NI). (2) RL lab supported by the Canadian Institutes of Health Research grant (PJT-148657). (3) C-IS lab supported by Ministry of Science and Technology, Taiwan (MOST 104-2320-B-006-010-MY2). (4) RA lab supported by European Research Council (ERC)-Consolidator Grant under the European Union's Horizon 2020 research and innovation program (grant agreement No. 682118) and Israel Science Foundation (grant agreement No. 1574/15).",

year = "2019",

month = aug,

day = "2",

doi = "10.3389/fonc.2019.00719",

language = "English",

volume = "9",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Editorial

T2 - WW Domain Proteins in Signaling, Cancer Growth, Neural Diseases, and Metabolic Disorders

AU - Chang, Nan Shan

AU - Lin, Rongtuan

AU - Sze, Chun I.

AU - Aqeilan, Rami I.

N1 - Funding Information: Funding. Grant supports for this work: (1) N-SC lab supported by the Ministry of Science and Technology, Taiwan (MOST 107-2320-B-006-058-MY3 and 107-2320-B-006-005) and the National Health Research Institute (NHRI-EX107-10734NI). (2) RL lab supported by the Canadian Institutes of Health Research grant (PJT-148657). (3) C-IS lab supported by Ministry of Science and Technology, Taiwan (MOST 104-2320-B-006-010-MY2). (4) RA lab supported by European Research Council (ERC)-Consolidator Grant under the European Union's Horizon 2020 research and innovation program (grant agreement No. 682118) and Israel Science Foundation (grant agreement No. 1574/15).

PY - 2019/8/2

Y1 - 2019/8/2

UR - http://www.scopus.com/inward/record.url?scp=85072734019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072734019&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00719

DO - 10.3389/fonc.2019.00719

M3 - Editorial

AN - SCOPUS:85072734019

SN - 2234-943X

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 719

ER -